Novartis, VANRAFIA

Novartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New Therapeutic Paradigm | DelveInsight

Published on 08/07/2025 at 18:03 | prnewswire.co.uk

DelveInsight Business Research, LLP United States of America United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/novartis-vanrafia-approval-disrupts-iga-nephropathy-market-paving-way-for-new-therapeutic-paradigm--delveinsight-302439404.html

en | boerse | 67996893 |